2014 ASCO ANNUAL MEETING
Forget those guidelines: With hard-to-beat NSCLC, 'Revel' in small victories
By Randy Osborne
Monday, June 2, 2014
CHICAGO Efficacy plus an acceptable safety profile add up to the prime outcome from a trial, but there's much value in lesser attempts, said Gregory Masters of the Helen F. Graham Cancer Center in Newark, Del., as he found himself defending the choice of a spotlighted study at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) over the weekend.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.